ARCA biopharma announced that Medtronic has extended the U.S., Canadian and European Clinical Trial Collaboration Agreement with ARCA for an additional year to April 2019.
Under the collaboration, Medtronic has supported clinical trial use of its continuous monitoring devices, managed atrial fibrillation burden data collection and managed analysis of patients’ cardiac rhythms, via a Medtronic device, either a previously implanted cardiac resynchronization or defibrillation device, or a previously or newly inserted Reveal® loop recorder.
“Medtronic has been a terrific partner in exploring and understanding atrial fibrillation in a clinical trial setting, Dr. Michael Bristow, MD, PhD, President and Chief Executive Officer of ARCA, said. “We are excited to extend our collaboration as we continue analysis of the trial data from GENETIC-AF and consider potential future development plans for Gencaro.”